February 20, 2024 News by Lindsey Shapiro, PhD Chronic inflammatory lesions linked to more aggressive MS in US study The presence in the brain of chronic inflammatory lesions ā called paramagnetic rim lesions (PRLs) ā in people with multiple sclerosis (MS) is associated with a greater relapse burden and faster disability progression in the long term, according to a new U.S. study. Among more than 150 patients who…
September 28, 2023 News by Marisa Wexler, MS Lemtrada controlled RRMS disease activity more than a decade Over more than a decade of treatment with Lemtrada (alemtuzumab), relapse rates were low and about half of people with relapsing-remitting multiple sclerosis (RRMS) remained free of confirmed disability worsening, according to final results from the open-label TOPAZ clinical trial. “To our knowledge, this report represents the longest…
September 22, 2023 News by Steve Bryson, PhD Menopause linked with lower MS relapse rate, increased disability Women with multiple sclerosis (MS) have significantly lower relapse rates after entering menopause, but disability levels increase significantly in that period, according to a pooled analysis of studies. The findings are consistent with a decrease in immune activity with age and loss of estrogen, leading to fewer disease-related relapses,…
February 23, 2023 News by InĆŖs Martins, PhD ACTRIMS 2023: Evobrutinib safely keeps relapse rates low after 4 years Evobrutinib, an experimental BTK inhibitor being developed for people with relapsing forms of multiple sclerosis (MS), continues to be well tolerated and is showing low relapse rates after four years of treatment. That’s according to new data spanning a Phase 2 trial (NCT02975349) that tested evobrutinib against…
August 29, 2022 News by Marisa Wexler, MS Ublituximab’s Benefits Over Aubagio Seen in ULTIMATE Clinical Trials Treatment with the experimental B-cell depleting therapy ublituximab significantly outperformed Aubagio (teriflunomide) at reducing relapse rates and the number of lesions in people with relapsing forms of multiple sclerosis (MS), according to updated data from the Phase 3 ULTIMATE clinical trials. The two medications had comparable effects…
October 13, 2021 News by Marisa Wexler, MS #ECTRIMS2021 ā Ponvory Effective in Early MS in OPTIMUM Trial Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ hereĀ to see the latest stories from the conference.
November 8, 2018 News by Santiago Gisler Pregnancy Briefly Lowers MS Relapse Rates and Treatment Reliance, Real-world Study Shows Relapse rates in women with multiple sclerosis (MS) decline during pregnancy, as does the use of disease-modifying therapies, before both adjust to pre-pregnancy levels again, a large U.S. study based on real-world data shows. The study, āRelapses and disease-modifying drug treatment in pregnancy and live birth…
February 27, 2017 News by Patricia Silva, PhD #ACTRIMS2017 – Novantrone Lowers Relapse Rates over Long Term, But Carries Cancer Risk Ten years after completingĀ treatment with Novantrone (mitoxantrone), a chemotherapy drug, multiple sclerosis (MS) patients showed evidence of markedly lowerĀ annualized relapse rates, but the therapy’s effects began to wane after five years, a studyĀ presented atĀ ACTRIMS 2017 ForumĀ reported. The study also assessed howĀ Novantrone affects disease progression in primary and secondary progressive…
September 21, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – 2 Rounds of Lemtrada Seen to Effectively Treat MS Relapses for Years Lemtrada (alemtuzumab) as a first treatment option for relapsing multiple sclerosis (MS) patients reduced relapse rates and disability progression throughout a study period of six years ā although most patients received treatment only in the first two years. The study showed that Lemtrada has the potential to harness disease activity…
April 4, 2016 News by Patricia Silva, PhD Young MS Patients in the US More Likely to Be Overweight and Suffer More Relapses Than Peers Elsewhere, Study Finds Scientists at the Pediatric MS Center at NYU Langone, New York, reported that U.S. adolescents withĀ multiple sclerosis (MS) receivingĀ interferon-beta 1a therapyĀ had a higher body mass index (BMI), more relapses, and were managed differently compared to patients of similar age in seven other countries. The study, “Subcutaneous…